Core Viewpoint - WuXi AppTec's CAR-T cell therapy, Rukiyou Lunsai injection, is making progress in negotiations to be included in the commercial health insurance innovative drug directory, which is expected to reduce patient medication costs and benefit more patients [1] Group 1 - WuXi AppTec's stock price increased by over 10%, reaching HKD 3.82 with a trading volume of HKD 4.63 million [1] - The CAR-T therapy is the first domestically approved Class 1 CAR-T product in China, with a post-launch pricing of RMB 1.29 million per injection [1] - On October 30, WuXi AppTec announced a strategic cooperation supplementary agreement with Regeneron Pharmaceuticals, marking a significant upgrade in their long-term partnership [1] Group 2 - The supplementary agreement allows WuXi AppTec to receive up to USD 50 million in payments, which includes milestone payments for the development of the MAGE-A4 product, regulatory oversight of drug manufacturing processes, option exercise fees, and milestone payments for lentiviral vector manufacturing processes [1]
药明巨诺-B涨超10% 报道称其CAR-T药物有望进入商保目录